**Vanderbilt Human Research Protection Program
Radioactive Drug Research Committee – Institutional Review Board
FDA Registration Number – RDRC0135**

The RDRC Committee meets the first Friday of every quarter at 10:00AM. Meeting locations are subject to change. Please call the VHRPP office to confirm meeting location (322-2918).

Effective – November 8, 2022

VOTING MEMBERS (5)

Eric Shinohara, M.D. - Chair

Gary Smith, M.D. - Vice Chair

Mary Keenan, DMP

Kenneth Lewis, PhD

Adam Rosenberg, PhD

Radiation Oncology

Nuclear Medicine

Radiology and Radiological Sciences

Radiology and Radiological Sciences

Imaging Science

Alternate Members

Diana Carver Lewis, PhD, DABR - Radiology and Radiological Sciences
Anuradha Chakravarthy, M.D. - Radiation Oncology
Jared Grice, PhD, DMP - Radiology and Radiological Sciences
Joseph Harper, PharmD - Nuclear Pharmacist
Chirayu Shah, M.D. - Nuclear Medicine

Vanderbilt’s Radioactive Drug Research Committee (RDRC) is authorized by the U.S. Food and Drug Administration (FDA) to approve research projects involving the use of certain “non-approved” radioactive drugs for pre-Phase 1 research which would otherwise require approval from the FDA in the form of an Investigational New Drug (IND). Use the RDRC application form embedded in the IRB application and guidelines to submit proposals to the RDRC. If you need help in completing and RDRC application and/or estimating the radiation dose, contact the IRB to have the Radiation Dose Calculation Member of the RDRC assist you.

For a list of radiation doses, or examples of risk statements, please go to the Radiation Dose Calculator.